CN103857697A - 形成金黄色葡萄球菌表位结合位点的肽或肽的组合 - Google Patents
形成金黄色葡萄球菌表位结合位点的肽或肽的组合 Download PDFInfo
- Publication number
- CN103857697A CN103857697A CN201280046452.2A CN201280046452A CN103857697A CN 103857697 A CN103857697 A CN 103857697A CN 201280046452 A CN201280046452 A CN 201280046452A CN 103857697 A CN103857697 A CN 103857697A
- Authority
- CN
- China
- Prior art keywords
- peptide
- combination
- antibody
- infection
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 111
- 241000191967 Staphylococcus aureus Species 0.000 title claims abstract description 62
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 32
- 208000015181 infectious disease Diseases 0.000 claims description 31
- 241001465754 Metazoa Species 0.000 claims description 20
- 210000004369 blood Anatomy 0.000 claims description 19
- 239000008280 blood Substances 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 16
- 206010040047 Sepsis Diseases 0.000 claims description 14
- 210000004027 cell Anatomy 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 10
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 9
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 9
- 208000037815 bloodstream infection Diseases 0.000 claims description 9
- 238000012360 testing method Methods 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 6
- 241000699802 Cricetulus griseus Species 0.000 claims description 5
- 206010056559 Graft infection Diseases 0.000 claims description 5
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 5
- 229960003085 meticillin Drugs 0.000 claims description 5
- 210000001672 ovary Anatomy 0.000 claims description 5
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 208000031482 Prosthesis-Related Infections Diseases 0.000 claims description 4
- 206010062255 Soft tissue infection Diseases 0.000 claims description 4
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 238000000502 dialysis Methods 0.000 claims description 4
- 208000011354 prosthesis-related infectious disease Diseases 0.000 claims description 4
- 241000238631 Hexapoda Species 0.000 claims description 3
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims description 3
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims description 3
- 210000004408 hybridoma Anatomy 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 20
- 239000002953 phosphate buffered saline Substances 0.000 description 20
- 230000001580 bacterial effect Effects 0.000 description 18
- 238000002965 ELISA Methods 0.000 description 12
- 210000003677 hemocyte Anatomy 0.000 description 12
- 229940000351 hemocyte Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002860 competitive effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 101710153593 Albumin A Proteins 0.000 description 3
- 208000031462 Bovine Mastitis Diseases 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000019254 respiratory burst Effects 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 102000000584 Calmodulin Human genes 0.000 description 1
- 108010041952 Calmodulin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 210000001557 animal structure Anatomy 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56938—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11182598.0 | 2011-09-23 | ||
| EP11182598 | 2011-09-23 | ||
| US201161545763P | 2011-10-11 | 2011-10-11 | |
| US61/545,763 | 2011-10-11 | ||
| PCT/EP2012/068703 WO2013041707A1 (en) | 2011-09-23 | 2012-09-21 | Peptide or arrangement of peptides forming a staphylococcus aureus epitope binding site |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103857697A true CN103857697A (zh) | 2014-06-11 |
Family
ID=47913924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201280046452.2A Pending CN103857697A (zh) | 2011-09-23 | 2012-09-21 | 形成金黄色葡萄球菌表位结合位点的肽或肽的组合 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9422365B2 (enExample) |
| EP (1) | EP2758431A1 (enExample) |
| JP (1) | JP2014534169A (enExample) |
| CN (1) | CN103857697A (enExample) |
| AU (1) | AU2012311428A1 (enExample) |
| WO (1) | WO2013041707A1 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
| CN119431528A (zh) * | 2024-10-28 | 2025-02-14 | 中国人民解放军陆军军医大学 | 一种金黄色葡萄球菌毒素LukG抗原表位肽及其应用 |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2616728T3 (es) | 2008-05-23 | 2017-06-14 | Siwa Corporation | Procedimientos y composiciones para facilitar la regeneración |
| US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
| US9944694B2 (en) * | 2013-12-13 | 2018-04-17 | Rijksuniversiteit Groningen | Antibodies against Staphylococcus aureus and uses therof |
| IL251210B2 (en) | 2014-09-19 | 2023-12-01 | Siwa Corp | Anti-aging antibodies for the treatment of inflammation and autoimmune disorders |
| US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
| US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
| CN109071675A (zh) | 2016-02-19 | 2018-12-21 | Siwa有限公司 | 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物 |
| CA3057829A1 (en) | 2016-04-15 | 2017-10-19 | Siwa Corporation | Anti-age antibodies for treating neurodegenerative disorders |
| EP3475306A1 (en) | 2016-06-23 | 2019-05-01 | Siwa Corporation | Vaccines for use in treating various diseases and disorders |
| US10858449B1 (en) * | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
| US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
| US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
| US10995151B1 (en) * | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
| US10919957B2 (en) | 2017-04-13 | 2021-02-16 | Siwa Corporation | Humanized monoclonal advanced glycation end-product antibody |
| US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072600A2 (en) * | 2001-01-26 | 2002-09-19 | Inhibitex, Inc. | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| WO2010133600A1 (en) * | 2009-05-18 | 2010-11-25 | Julius-Maximilians-Universität Würzburg | Antibodies or fragments thereof directed against a staphylococcus aureus epitope of isaa or isab |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009031009A (ja) * | 2007-07-24 | 2009-02-12 | St Marianna Univ School Of Medicine | 黄色ブドウ球菌の検出または同定方法および検出キット |
-
2012
- 2012-09-21 WO PCT/EP2012/068703 patent/WO2013041707A1/en not_active Ceased
- 2012-09-21 AU AU2012311428A patent/AU2012311428A1/en not_active Abandoned
- 2012-09-21 EP EP12759781.3A patent/EP2758431A1/en not_active Withdrawn
- 2012-09-21 CN CN201280046452.2A patent/CN103857697A/zh active Pending
- 2012-09-21 US US14/346,435 patent/US9422365B2/en not_active Expired - Fee Related
- 2012-09-21 JP JP2014531256A patent/JP2014534169A/ja not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072600A2 (en) * | 2001-01-26 | 2002-09-19 | Inhibitex, Inc. | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| WO2010133600A1 (en) * | 2009-05-18 | 2010-11-25 | Julius-Maximilians-Universität Würzburg | Antibodies or fragments thereof directed against a staphylococcus aureus epitope of isaa or isab |
Non-Patent Citations (1)
| Title |
|---|
| UDO LORENZ ET AL.: "Functional Antibodies Targeting IsaA of Staphylococcus aureus Augment Host Immune Response and Open New Perspectives for Antibacterial Therapy", 《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109021109A (zh) * | 2018-07-20 | 2018-12-18 | 上海交通大学 | 一种牛源性抗金黄色葡萄球菌融合抗体scFv-Fc及其制备方法 |
| CN119431528A (zh) * | 2024-10-28 | 2025-02-14 | 中国人民解放军陆军军医大学 | 一种金黄色葡萄球菌毒素LukG抗原表位肽及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012311428A1 (en) | 2014-04-24 |
| WO2013041707A1 (en) | 2013-03-28 |
| EP2758431A1 (en) | 2014-07-30 |
| US9422365B2 (en) | 2016-08-23 |
| US20140234339A1 (en) | 2014-08-21 |
| JP2014534169A (ja) | 2014-12-18 |
| AU2012311428A2 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103857697A (zh) | 形成金黄色葡萄球菌表位结合位点的肽或肽的组合 | |
| US9658230B2 (en) | Antibodies or fragments thereof directed against a Staphylococcus aureus epitope of IsaA or IsaB | |
| JP2008179634A (ja) | グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体 | |
| JPS62187417A (ja) | 緑膿菌血清型に対する交さ反応性かつ交さ防御性単クロ−ン性抗体 | |
| JP2010013454A (ja) | グラム陽性細菌のペプチドグリカンに対する多機能性モノクローナル抗体 | |
| JPH0284197A (ja) | ヒトモノクローナル抗体 | |
| WO1986002358A1 (en) | Monoclonal antibodies and their use | |
| WO1986002364A1 (en) | Monoclonal antibodies and their use | |
| JP2005514053A6 (ja) | グラム陽性細菌のリポタイコ酸に特異的なオプソニン性モノクローナルおよびキメラ抗体 | |
| EP0176365A2 (en) | Human monoclonal antibody and its preparation | |
| WO1986002365A1 (en) | Monoclonal antibodies and their use | |
| Gaultier | Humoral immunity in patients with chronic kidney disease and their response to pneumococcal immunization | |
| Neely et al. | Comparison of pre-versus post-sepsis treatment with polyclonal immunoglobulin versus O serotype specific monoclonal antibody in burned Pseudomonas aeruginosa infected mice | |
| JP2587770B2 (ja) | 形質転換細胞 | |
| WO1986002360A1 (en) | Monoclonal antibodies and their use | |
| CN116761619A (zh) | 用于预防或治疗金黄色葡萄球菌感染性疾病的新型组合物 | |
| JPH02231096A (ja) | ヒトモノクローナル抗体 | |
| WO1987006468A1 (en) | Monoclonal antibodies and their use | |
| WO1986000643A1 (en) | Monoclonal antibodies and their use | |
| KR20130121443A (ko) | 설파메타진에 특이적인 단일클론항체 및 이를 생산하는 하이브리도마 세포 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140611 |
|
| WD01 | Invention patent application deemed withdrawn after publication |